News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Johnson & Johnson (JNJ) Gets $1.2 Billion Risperdal Judgment Tossed Out


3/21/2014 7:34:00 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Johnson & Johnson (JNJ:US) persuaded the Arkansas Supreme Court to throw out a $1.2 billion award against the drugmaker over its marketing of the antipsychotic drug Risperdal, erasing the biggest state verdict involving the controversial medicine. Arkansas’s highest court concluded today that state officials relied on the wrong law to challenge the Risperdal marketing campaign and that a judge erred in setting the $1.2 billion in fines for violations of the state’s Medicaid fraud statute. J&J’s Janssen unit was accused of making misleading claims about Risperdal’s effectiveness and downplaying its diabetes risks on warning labels.

Help employers find you! Check out all the jobs and post your resume.

Read at BusinessWeek
Read at SF Gate
Read at Reuters
Read at New York Times
Read at USA Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES